Geron Forecasts $220M-$240M RYTELO Revenue, TD Cowen Cuts PT to $3
Geron forecasted 2026 RYTELO net revenue of $220 million to $240 million and operating expenses of $230 million to $240 million, projecting a year-over-year expense reduction. On January 29, TD Cowen trimmed its price target to $3 from $4 while maintaining a Buy rating ahead of Q4 results on February 25.
1. Analyst Price Target Adjustment
On January 29, TD Cowen analyst Tara Bancroft reduced Geron’s price target from $4 to $3 and reiterated a Buy rating. This adjustment reflects updated expectations ahead of the company’s fourth-quarter financial results scheduled for February 25.
2. 2026 Financial Guidance
Geron projects RYTELO net product revenue between $220 million and $240 million for 2026, with total operating expenses forecast at $230 million to $240 million. Management anticipates a year-over-year reduction in operating expenses, reinforcing the company’s balance sheet strength.
3. Strategic Operational Priorities
Key priorities include expanding RYTELO’s commercial launch in the US, exploring lower-risk myelodysplastic syndromes markets outside the US, and advancing the Phase 3 IMpactMF trial. These initiatives aim to drive revenue growth and broaden the treatment’s market opportunity.
4. Upcoming Fourth-Quarter Results
Geron plans to report fourth-quarter and full-year 2025 results on February 25. Investors will focus on revenue performance, expense trends, and progress on commercial and clinical milestones when results are announced.